Drug Profile
Cetuximab biosimilar - Mabion
Alternative Names: MabionEGFRLatest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator Mabion
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in Poland (IV)
- 10 Jun 2015 Mabion plans clinical trial for Cancer in Poland in 2016-2017 (Mabion website, June 2015)